Examples: breast cancer, NCT03147287, pd-l1

Top 100 results for: "prostate cancer"

Not Enrolling

A Phase 2, Randomized Study of Proscavax, a PSA/IL-2/GM-CSF Vaccine, in Treatment-naive Patients with Clinically Localized Prostate Cancer Versus an Active Surveillance Strategy

Trial Description: This study will evaluate the safety and efficacy of a prostate cancer vaccine named Proscavax (Prostate-specific antigen(PSA) / Interleukin-2(IL-2) / Granulocyte-macrophage colony-stimulating factor(GM-CSF)) in patients with localized prostate cancer. The goal of the study is to determine if vaccine administration results in a change in the rate of prostate cancer progression when compared to a no-treatment control group of active surveillance patients. The researchers are interested in evaluating the proportion of participants with prostate cancer progression at 2 years

  • Conditions: prostate cancer
  • Phase: II
  • Trial ID: NCT03579654
  • Protocol ID: 18-076

Enrolling

A Phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC)

Trial Description: This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination is effective in shrinking or preventing the growth of metastatic prostate cancer. The names of the study drugs involved in this study are: - Talazoparib - Tazemetostat

  • Conditions: metastatic castration-resistant prostate cancer, metastatic prostate cancer
  • Phase: I
  • Trial ID: NCT04846478
  • Protocol ID: 21-086

Not Enrolling

Identification of Men with a genetic predisposition to Prostate Cancer: Targeted Screening in men at higher genetic risk and controls (The IMPACT study)

Trial Description: The IMPACT study is an international targeted prostate screening study of men at increased prostate cancer risk due to the presence of known pathogenic mutations in BRCA1 and BRCA2 genes. There are only approximately 150 men with a known BRCA1 or BRCA2 mutation in the UK. Research has shown that these men are at an increased risk of developing prostate cancer but more information is needed about the pathogenesis of prostate cancer in this defined group and the role of screening in these men. The study will offer annual PSA screening to these men to determine the incidence

  • Conditions: prostate cancer in brca1 and brca2 carriers
  • Phase: Not Applicable
  • Trial ID: NCT00261456
  • Protocol ID: 17-077

Enrolling

NRG-GU009: Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)

Trial Description: This phase III trial compares less intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in treating patients with high risk prostate cancer and low gene risk score. This trial also compares more intense hormone therapy and radiation therapy to usual hormone therapy and radiation therapy in patients with high risk prostate cancer and high gene risk score. Apalutamide may help fight prostate cancer by blocking the use of androgen by the tumor cells. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Giving

  • Conditions: metastatic malignant neoplasm in the bone, prostate adenocarcinoma, stage iii prostate cancer ajcc v8, stage iiia prostate cancer ajcc v8, stage iiib prostate cancer ajcc v8, stage iiic prostate cancer ajcc v8, stage iva prostate cancer ajcc v8
  • Phase: III
  • Trial ID: NCT04513717
  • Protocol ID: 21-031

Enrolling

NRG-GU008, Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer after Radical Prostatectomy (INNOVATE*)

Trial Description: This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.

  • Conditions: prostate adenocarcinoma, stage i prostate cancer ajcc v8, stage ii prostate cancer ajcc v8, stage iia prostate cancer ajcc v8, stage iib prostate cancer ajcc v8, stage iic prostate cancer ajcc v8, stage iii prostate cancer ajcc v8, stage iiia prostate cancer ajcc v8, stage iiib prostate cancer ajcc v8, stage iiic prostate cancer ajcc v8, stage iva prostate cancer ajcc v8
  • Phase: III
  • Trial ID: NCT04134260
  • Protocol ID: 20-651

Not Enrolling

COMbination of Bipolar Androgen Therapy and Nivolumab in Patients with Metastatic Castration-Resistant Prostate Cancer [COMBAT-CRPC]

Trial Description: Single arm, multicenter, open-label Phase II study of the effects of parenteral testosterone in combination with nivolumab in men with metastatic castration-resistant prostate cancer who previously progressed on at least one novel androgen-receptor targeted therapy (i.e. Abiraterone acetate, Enzalutamide). Up to one taxane agent is permitted.

  • Conditions: castration-resistant prostate cancer, metastatic prostate cancer, prostate cancer
  • Phase: II
  • Trial ID: NCT03554317
  • Protocol ID: 19-096

Enrolling

A Phase III Double Blinded Study of Early Intervention after RADICAl ProstaTEctomy with Androgen Deprivation Therapy with Darolutamide vs. Placebo in Men at Highest Risk of Prostate Cancer Metastasis by Genomic Stratification (ERADICATE)

Trial Description: This phase III trial compares the effect of adding darolutamide to ADT versus ADT alone after surgery for the treatment of high-risk prostate cancer. ADT reduces testosterone levels in the blood. Testosterone is a hormone made mainly in the testes and is needed to develop and maintain male sex characteristics, such as facial hair, deep voice, and muscle growth. It also plays role in prostate cancer development. Darolutamide blocks the actions of the androgens (e.g. testosterone) in the tumor cells and in the body. Giving darolutamide with ADT may work better in eliminating or reducing the size of the cancer and/or prevent it from returning compared to ADT alone in patients with prostate cancer.

  • Conditions: prostate carcinoma
  • Phase: III
  • Trial ID: NCT04484818
  • Protocol ID: 22-136

Enrolling

A Phase 2 Study of Neratinib in Patients with Metastatic Castration Resistant Prostate Cancer and Increased Human Epithelial Growth Factor Receptor 2 (HER2) Signaling

Trial Description: This research study is examining whether Neratinib has any activity in participants with prostate cancer that has spread and is no longer responding to hormonal treatment. - The names of the study drug involved in this study is neratinib.

  • Conditions: castration-resistant prostate cancer, metastatic prostate adenocarcinoma, prostate cancer, prostate cancer metastatic
  • Phase: II
  • Trial ID: NCT04781374
  • Protocol ID: 20-659

Not Enrolling

A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Trial Description: This research study is studying the use of a targeted therapy called LY SARM, which is an investigational drug from a new class of molecules called Selective Androgen Receptor Modulators (SARMs) as a possible improvement in quality of life for participants who have undergone radical prostatectomy. Androgens are a group of hormones that play a role in male traits and reproductive activity. The names of the study interventions involved in this study are: - LY2452473

  • Conditions: prostate cancer
  • Phase: II
  • Trial ID: NCT02499497
  • Protocol ID: 15-120

Enrolling

Improving Quality of Life of Prostate Cancer Survivors with Androgen Deficiency

Trial Description: The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer who have undergone radical prostatectomy.

  • Conditions: prostate cancer
  • Phase: II
  • Trial ID: NCT03716739
  • Protocol ID: 18-733

Enrolling

Genetic Testing for Breast, Ovarian, Pancreatic and Prostate Cancers – GeneBOPP

Trial Description: This study is evaluating the effect of two pre-test education methods on participants interested in genetic testing for hereditary cancer risk.

  • Conditions: breast cancer, metastatic prostate cancer, ovarian cancer, pancreatic cancer
  • Phase: Not Applicable
  • Trial ID: NCT04330716
  • Protocol ID: 19-652

Enrolling

"A Phase 2 Study of Nivolumab in Patients with High-Risk Biochemically Recurrent Prostate Cancer"

Trial Description: This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer. The drug involved in this study is: -Nivolumab

  • Conditions: prostate cancer
  • Phase: II
  • Trial ID: NCT03637543
  • Protocol ID: 18-249

Enrolling

A Phase II Multi-Center Trial of Abemaciclib with or without Atezolizumab in Metastatic Castration Resistant Prostate Cancer

Trial Description: This trial is testing whether a molecularly targeted chemotherapy drug called abemaciclib and an immunotherapy drug called atezolizumab, alone or in combination, are effective in shrinking or preventing the growth of metastatic prostate cancer. The trial is also testing the safety of the combination of abemaciclib with atezolizumab.

  • Conditions: metastatic castration-resistant prostate cancer, prostate cancer
  • Phase: II
  • Trial ID: NCT04751929
  • Protocol ID: 20-701

Enrolling

RELAY: Repeated Magnetic Resonance Imaging Examinations to Analyze and Assess Your Cancer: A Prospective Study on the Use of Serial Magnetic Resonance Imaging in the Assessment of Changes during Treatment with Radiation Therapy

Trial Description: This is a phase 1 study to determine the feasibility and utility of using serial magnetic resonance imaging (MRI) to assess treatment response during and after radiation therapy (standard of care cancer treatment) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include three MRI scans (one pre treatment, during and post standard care cancer radiation therapy) for participants with advanced esophageal cancer, glioblastoma, prostate cancer, vulvar cancer or pediatric glioma. The research study procedures include: - Screening for eligibility - Three MRI scans

  • Conditions: esophageal cancer, glioblastoma, magnetic resonance imaging, mri, pediatric glioblastoma multiforme, prostate cancer, radiotherapy, vulvar cancer
  • Phase: I
  • Trial ID: NCT04188535
  • Protocol ID: 19-573

Not Enrolling

CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination with Enzalutamide or Abiraterone/Prednisone In Chemotherapy Naïve Subjects with Metastatic Castration Resistant Prostate Cancer

Trial Description: A phase 1b/2 study to examine taz in combination with enz or abi/pred in patients with metastatic castration resistant prostate cancer

  • Conditions: metastatic prostate cancer
  • Phase: I/II
  • Trial ID: NCT04179864
  • Protocol ID: 21-105

Not Enrolling

Genetic Counseling Processes and Outcomes Among Males with Prostate Cancer (ProGen)

Trial Description: This randomized controlled trial aims to evaluate the impact of pre-test video education and post-test genetic counseling as compared to in-person pre-test genetic counseling in males with advanced prostate cancer.

  • Conditions: prostate cancer
  • Phase: Not Applicable
  • Trial ID: NCT03328091
  • Protocol ID: 17-409

Enrolling

A Phase II Multi-Institutional Trial to Evaluate Prostate Specific Membrane Antigen (PSMA)-Based PET Imaging of High Risk Prostate Cancer

Trial Description: Background: People with prostate cancer usually have their cancer imaged with a CT scan and bone scan. They then have their prostate gland removed. Researchers want to test a scan that might predict if prostate cancer will return after this surgery. Objective: To test if a PET/CT scan before the prostate gland is removed can predict if prostate cancer will return. Also, to test if this approach is better or worse than the usual approach for prostate cancer. Eligibility: Men ages 18 and older with prostate cancer that appears to be contained within the prostate

  • Conditions: prostate cancer
  • Phase: II
  • Trial ID: NCT03976843
  • Protocol ID: 19-667

Enrolling

Exercise to Enhance Cardiovascular Health among Black Prostate Cancer Patients with Androgen Deprivation Therapy: POWER Trial

Trial Description: The purpose of this research is to determine whether a 16-week culturally tailored, technology-based, aerobic and resistance exercise intervention improves cardiovascular risk factors in Black men diagnosed with prostate cancer and are undergoing androgen deprivation therapy (ADT), and whether it will also improve physical fitness and function, body composition, and outcomes such as quality of life, cancer symptoms, and self-esteem. Participants in this study will be randomly assigned to one of two groups: 1) Aerobic and resistance exercise, or 2) Usual care.

  • Conditions: androgen deprivation therapy, prostate cancer, prostate cancer metastatic
  • Phase: Not Applicable
  • Trial ID: NCT05327465
  • Protocol ID: 21-741

Not Enrolling

A Randomized, Phase II Study Evaluating the Addition of Pembrolizumab (MK-3475) to Radium-223 in Metastatic Castration Resistant Prostate Cancer (mCRPC).

Trial Description: This research study is studying the safety and tolerability of an investigational combination of drugs, radium-223 plus pembrolizumab as a possible treatment for castration-resistant prostate cancer. The interventions involved in this study are: - Radium-223 - Pembrolizumab

  • Conditions: prostate cancer
  • Phase: II
  • Trial ID: NCT03093428
  • Protocol ID: 16-498

Not Enrolling

DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation in very high risk, clinically loc

Trial Description: The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high risk of recurrence.

  • Conditions: prostate cancer
  • Phase: III
  • Trial ID: NCT04136353
  • Protocol ID: 21-464

Not Enrolling

Exercise Intervention among Men with Prostate Cancer Initiating Androgen Deprivation Therapy: Pilot Study

Trial Description: This research study is evaluating the impact and feasibility of a 12-week brisk walking and moderate strength training exercise intervention including a virtual component in men who are initiating androgen deprivation therapy (ADT) for prostate cancer

  • Conditions: prostate cancer
  • Phase: Feasibility / Pilot
  • Trial ID: NCT03070145
  • Protocol ID: 16-515

Not Enrolling

MOBILE HEALTH APP TO MITIGATE THE METABOLIC EFFECTS OF ANDROGEN DEPRIVATION THERAPY: A RANDOMIZED PILOT TRIAL IN MEN NEWLY TREATED WITH ANDROGEN DEPRIVATION THERAPY

Trial Description: This research study seeks to develop and evaluate a mobile health app which aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habits.

  • Conditions: prostate cancer
  • Phase: Not Applicable
  • Trial ID: NCT03761160
  • Protocol ID: 17-692

Not Enrolling

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA after Radical Prostatectomy with Adverse Features. Facilitating Optimal Radiation Management Using Leuprolide, Abiraterone Acetate, and Apalutamide (FORMULA-509 Trial)

Trial Description: This research study is comparing two different combinations of androgen deprivation therapy (ADT) used together with radiation as a treatment for rising PSA after radical prostatectomy (prostate cancer).

  • Conditions: prostate cancer
  • Phase: II
  • Trial ID: NCT03141671
  • Protocol ID: 16-623

Enrolling

Metacure: Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Prostatic Adenocarcinoma

Trial Description: The purpose of this study is to test if treatment with medications that reduce the male hormone level in the participant's body for a few months before surgery can shrink prostate cancer as much as possible, which might reduce the chances of the cancer coming back in the future. These treatments include a hormone injection given monthly or every three months and the study drugs, which include abiraterone acetate, prednisone, and apalutamide. These medications are being used in combination with surgery and maybe radiotherapy because studies have shown that any single

  • Conditions: prostate cancer
  • Phase: II
  • Trial ID: NCT03436654
  • Protocol ID: 18-429

Not Enrolling

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate plus Prednisone with or without Abemaciclib in Patients with Metastatic Castration-Resistant Prostate Cancer

Trial Description: This study is being done to see how safe and effective abemaciclib is when given together with abiraterone acetate plus prednisone in participants with metastatic castration resistant prostate cancer. Prednisolone may be used instead of prednisone per local regulation.

  • Conditions: prostate cancer
  • Phase: II/III
  • Trial ID: NCT03706365
  • Protocol ID: 19-212

Not Enrolling

A Phase 3 Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer

Trial Description: This is a randomized, open-label, three-arm, phase 3 study in men with biochemically recurrent prostate cancer and PSA doubling time ≤ 9 months at the time of study entry.

  • Conditions: prostate cancer
  • Phase: III
  • Trial ID: NCT03009981
  • Protocol ID: 17-384

Enrolling

INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Phase II Trial of Radiation Therapy and Darolutamide for Prostate Cancer

Trial Description: This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer. More specifically, this research would help determine whether this new form of hormonal therapy is as effective as the standard hormone therapy while also preserving erectile function.

  • Conditions: prostate cancer
  • Phase: II
  • Trial ID: NCT04025372
  • Protocol ID: 19-202

Not Enrolling

VISION: AN INTERNATIONAL, PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE 3 STUDY OF 177LU-PSMA-617 IN THE TREATMENT OF PATIENTS WITH PROGRESSIVE PSMA-POSITIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC)

Trial Description: The primary objective of this study was to compare the two alternate primary endpoints of radiographic progression-free survival (rPFS) and overall survival (OS) in patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who received 177Lu-PSMA-617 in addition to best supportive/best standard of care (BSC/BSoC) versus patients treated with best supportive/best standard of care alone.

  • Conditions: prostate cancer
  • Phase: III
  • Trial ID: NCT03511664
  • Protocol ID: 18-425

Not Enrolling

A prospective, Phase 3, multi-center, single-arm, imaging study investigating the safety and diagnostic performance of rhPSMA-7.3(18F) PET ligand in men with newly diagnosed prostate cancer

Trial Description: A prospective, Phase 3, multi center, single-arm, imaging study investigating the safety and diagnostic performance of Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA) 7.3 (18F) Positron Emission Tomography (PET) ligand in men with newly diagnosed prostate cancer.

  • Conditions: prostate cancer
  • Phase: III
  • Trial ID: NCT04186819
  • Protocol ID: 20-073

Enrolling

A randomized Phase III study Conventional Androgen Deprivation Therapy with or without Abiraterone acetate + prednisone and Apalutamide following a detectable PSA After Radiation and Androgen Deprivation Therapy: A randomized Clinical Trial in Men with High Risk Prostate Cancer.

Trial Description: This research study is being offered to those patients who have received radiation therapy and who are receiving long-term hormonal therapy for their prostate cancer and whose PSA remains detectable despite having received at least 6, but no more than 12 months of hormonal therapy. The name of the study drugs involved in this study is: - LHRHA (luteinizing hormone-releasing hormone agonist or antagonist) - Abiraterone Acetate - Apalutamide - Prednisone

  • Conditions: prostate cancer
  • Phase: III
  • Trial ID: NCT03777982
  • Protocol ID: 18-530

Enrolling

A Phase 1, Multi-Center, Open-Label, Dose Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics cf CC-94676 In Subjects with Metastatic Castration-Resistant Prostate Cancer

Trial Description: The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

  • Conditions: prostatic neoplasms
  • Phase: I
  • Trial ID: NCT04428788
  • Protocol ID: 20-367

Enrolling

Pilot study of an implantable microdevice for evaluating drug responses in situ in prostate cancer

Trial Description: In this research study, is assessing the feasibility of using an MR-guided implantable microdevice to measure tumor response to chemotherapy and other clinically relevant drugs in participants that have prostate cancer and are scheduled for a radical prostatectomy. The name of the study intervention involved in this study is: - Implantation of a MR-guided microdevice

  • Conditions: prostate cancer, radical prostatectomy
  • Phase: Feasibility / Pilot
  • Trial ID: NCT04399876
  • Protocol ID: 19-599

Not Enrolling

A Phase 2 Efficacy and Safety Study of Niraparib in Men with Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

Trial Description: The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration-resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies.

  • Conditions: prostatic neoplasms
  • Phase: II
  • Trial ID: NCT02854436
  • Protocol ID: 16-493

Not Enrolling

Phase IB Trial of Radium-223 and Niraparib in Patients with Castrate Resistant Prostate Cancer

Trial Description: This phase Ib trial studies the side effects and best dose of niraparib when given together with radium Ra223 dichloride in treating subjects with prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels and has spread from the primary site to the bone. Radium Ra 223 dichloride, acts like calcium to target cancer in the bones and may deliver radiation directly to the bone tumors, limiting damage to the surrounding normal tissue. Niraparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving radium Ra 223 dichloride and niraparib may work better in treating subjects with hormone-resistant prostate cancer metastatic to the bone.

  • Conditions: hormone-refractory prostate cancer, prostate carcinoma metastatic to the bone, stage iv prostate adenocarcinoma
  • Phase: I
  • Trial ID: NCT03076203
  • Protocol ID: 17-698

Not Enrolling

A Phase 2 Study of M6620 in Combination with Carboplatin compared with Docetaxel in Combination with Carboplatin in Metastatic Castration-Resistant Prostate Cancer

Trial Description: This phase II trial studies how well berzosertib (M6620) and carboplatin with or without docetaxel works in treating patients with castration-resistant prostate cancer that has spread to other places in the body (metastatic). M6620 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving M6620, carboplatin and docetaxel may work better in treating patients with metastatic castration-resistant prostate cancer compared to carboplatin and docetaxel alone.

  • Conditions: castration-resistant prostate carcinoma, metastatic prostate carcinoma, stage iv prostate cancer ajcc v8
  • Phase: II
  • Trial ID: NCT03517969
  • Protocol ID: 19-715

Enrolling

Preventing a Decline in Physical Function in Older Androgen-Deprived Men with Structured Exercise Training (RESIST-ADT Trial)

Trial Description: The overall goal of this study is to determine if implementing structured exercises prevent decline in muscle mass, muscle strength and physical function in men with prostate cancer undergoing androgen deprivation therapy (ADT). Our main hypothesis is that structured resistance exercise training in men undergoing ADT will preserve physical function assessed by loaded stair climbing power compared with the control group. The trial will also examine the efficacy of the exercise regimen on muscle strength, QOL and fatigue. The findings of this trial will lay the groundwork for definitive intervention trials to prevent frailty and falls in these men.

  • Conditions: physical function, prostate cancer
  • Phase: II
  • Trial ID: NCT04485767
  • Protocol ID: 20-193

Not Enrolling

A Phase 1 Dose Escalation and Expanded Cohort Study of PF-06821497 in the Treatment of Adult Patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) and Follicular Lymphoma (FL)

Trial Description: A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).

  • Conditions: castration resistant prostate cancer (crpc), follicular lymphoma (fl), small cell lung cancer (sclc)
  • Phase: I
  • Trial ID: NCT03460977
  • Protocol ID: 18-159

Not Enrolling

An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced solid/metastatic tumours

Trial Description: A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.

  • Conditions: advanced solid tumors, metastatic breast cancer, metastatic castration-resistant prostate cancer, non-small cell lung cancer
  • Phase: I/II
  • Trial ID: NCT03568656
  • Protocol ID: 21-430

Not Enrolling

The MAP Trial: Phase III Study Of Muscadine Plus (MPX) In Men With Prostate Cancer: A Randomized Double-Blind, Placebo-Controlled Study Of The Effects Of MPX Capsules On Rising Prostate-Specific Antigen Levels In Alanine/Alanine SOD2 Genotype Men Following Initial Therapy For Prostate Cancer

Trial Description: This research is being done to determine if men with rising PSA after initial therapy for localized prostate cancer who display the Alanine/Alanine SOD2 genotype of MnSOD and supplement their diet with MPX have greater decrease in PSA slope following treatment compared to men that do not supplement with MPX.

  • Conditions: adenocarcinoma of the prostate
  • Phase: III
  • Trial ID: NCT03535675
  • Protocol ID: 18-525

Not Enrolling

A Phase 2 Study of Onvansertib (PCM-075) in Combination with Abiraterone and Prednisone in Patients with Metastatic Castration-Resistant Prostate Cancer

Trial Description: The purpose of the phase 2 study is to determine whether Onvansertib is safe and tolerable in adult participants with Metastatic Castration-Resistant Prostate Cancer who have disease progression while receiving abiraterone acetate (abiraterone) and prednisone therapy, and to observe the effects of Onvansertib in combination with abiraterone and prednisone on disease control.

  • Conditions: metastatic castration-resistant prostate cancer
  • Phase: II
  • Trial ID: NCT03414034
  • Protocol ID: 18-117

Not Enrolling

A Phase 2 Multicohort Study of Nivolumab in Combination with Docetaxel and Androgen Deprivation Therapy in Metastatic Hormone Sensitive Prostate Cancer Patients with DNA Damage Repair Defects or Inflamed Tumors

Trial Description: This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer. The names of the study drugs involved in this study are: - Androgen deprivation therapy (ADT) with a drug of your physician's choice. This may include leuprolide (Lupron), goserelin acetate (Zoladex), or degarelix (Firmagon). - Docetaxel - Nivolumab

  • Conditions: hormone sensitive prostate cancer, metastasis prostate adenocarcinoma, prostate adenocarcinoma
  • Phase: II
  • Trial ID: NCT04126070
  • Protocol ID: 19-384

Enrolling

Testing Home-based Exercise Strategies to Improve Exercise Participation and Cardiovascular Health in Underserved Minority Patients with Cancer Undergoing Chemotherapy: the THRIVE Study

Trial Description: The purpose of this research is to determine whether a 16 week, home-based, aerobic and resistance exercise intervention will increase physical activity levels in Black and Hispanic breast, colorectal, or prostate cancer patients. The names of the study interventions involved in this study are: - Supervised aerobic and resistance exercise (SUP) - virtually supervised 16- week aerobic and resistance exercise performed at home via Zoom. - Unsupervised aerobic and resistance exercise (UNSUP) - home-based 16- week aerobic and resistance exercise. - Attention control (AC) - 16-week home-based stretching.

  • Conditions: breast cancer, colorectal cancer, prostate cancer
  • Phase: Not Applicable
  • Trial ID: NCT05327452
  • Protocol ID: 21-559

Not Enrolling

An Exploratory Study of Nivolumab with or without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants with Advanced Metastatic Cancer

Trial Description: This is an open-label, exploratory study to evaluate nivolumab with or without ipilimumab based on percentage of tumoral CD8 cells at the time of treatment in participants with varying advanced solid tumors. Participants who have a tumor with ≥ 15% CD8 cells (classified as CD8 high) will receive nivolumab monotherapy, and participants who have a tumor with < 15% CD8 cells (classified as CD8 low) will receive ipilimumab in combination with nivolumab

  • Conditions: advanced metastatic cancer, advanced prostate cancer
  • Phase: Feasibility / Pilot
  • Trial ID: NCT03651271
  • Protocol ID: 18-741

Not Enrolling

ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer

Trial Description: This is a two-arm, open label Phase 1b/2 study with an oral administration of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone in male patients with metastatic Castration Resistant Prostate Cancer. This study is designed to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) based on safety, tolerability, pharmacokinetic, and efficacy profiles of CPI-1205 in combination with either enzalutamide or abiraterone/prednisone. Following determination of MTD and RP2D will proceed to phase 2. Patients in phase 2 will receive CPI-1205 at the RP2D in combination with either enzalutamide or abiraterone/prednisone vs either enzalutamide or abiraterone/prednisone as a control arm.

  • Conditions: metastatic castration resistant prostate cancer (mcrpc)
  • Phase: I/II
  • Trial ID: NCT03480646
  • Protocol ID: 18-112

Enrolling

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy

Trial Description: The purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer results in an improvement in pathological complete response (pCR) rate and metastasis-free survival (MFS) as compared to placebo plus ADT.

  • Conditions: prostatic neoplasms
  • Phase: III
  • Trial ID: NCT03767244
  • Protocol ID: 19-140

Not Enrolling

A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS

Trial Description: Avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors, including non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), hormone receptor positive (HR+) breast cancer, recurrent platinum sensitive ovarian cancer, urothelial cancer (UC), and castration resistant prostate cancer (CRPC).

  • Conditions: avelumab in combination with talazoparib will be investigated in patients with locally advanced (primary or recurrent) or metastatic solid tumors
  • Phase: I/II
  • Trial ID: NCT03330405
  • Protocol ID: 17-687

Enrolling

OPTimizing Treatment Focused Genetic Testing IN Advanced Cancer- OPT-IN

Trial Description: This two-part randomized controlled trial aims to evaluate the impact of pre-test video education as compared to pre-test Chatbot education

  • Conditions: breast cancer, ovarian cancer, pancreatic cancer, prostate cancer
  • Phase: Not Applicable
  • Trial ID: NCT04066361
  • Protocol ID: 19-068

Not Enrolling

An open-label phase 1b study to determine the maximum tolerated and/or recommended phase 2 dose of the ATR inhibitor elimusertib (BAY 1895344) in combination with PARP inhibitor niraparib, in participants with recurrent advanced solid tumors and ovarian cancer

Trial Description: The purpose of the study is to test how well patients with advanced solid tumors and ovarian cancer respond to treatment with elimusertib in combination with niraparib. In addition researchers want to find for patients the optimal dose of elimusertib in combination with niraparib, how the drug is tolerated and the way the body absorbs, distributes and discharges the drug. The study medication elimusertib works by blocking a substance produced by the body (ATR Kinase) which is important for the growth of tumor cells. Niraparib works by blocking a substance produced by the body (PARP enzymes) in a way that tumor cells can be killed, or made more susceptible to chemotherapy.

  • Conditions: advanced solid tumors (excluding prostate cancer), ovarian cancer
  • Phase: I/II
  • Trial ID: NCT04267939
  • Protocol ID: 19-810

Not Enrolling

Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

Trial Description: This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells

  • Conditions: metastatic castration resistant prostate cancer, renal cell cancer
  • Phase: I
  • Trial ID: NCT02655822
  • Protocol ID: 16-150